Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol Fumarate Pressair vs Perforomist in COPD
NCT02796651Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of formoterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by AstraZeneca. Primary endpoint: Normalized Forced Expiratory Volume in 1 Second Area Under the Curve Over 12 Hours at Day 7. Started Jun 2016; status: completed.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02796651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02796651.